Amneal Pharmaceuticals (AMRX) Scheduled to Post Earnings on Friday

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) is scheduled to release its earnings data before the market opens on Friday, May 3rd. Analysts expect Amneal Pharmaceuticals to post earnings of $0.08 per share for the quarter. Amneal Pharmaceuticals has set its FY 2024 guidance at 0.530-0.630 EPS.Persons interested in participating in the company's earnings conference call can do so using this link.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Friday, March 1st. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.05 by $0.07. Amneal Pharmaceuticals had a positive return on equity of 126.04% and a negative net margin of 3.51%. The business had revenue of $616.98 million during the quarter, compared to the consensus estimate of $630.67 million. On average, analysts expect Amneal Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Amneal Pharmaceuticals Trading Down 0.5 %

Shares of AMRX traded down $0.03 during midday trading on Friday, reaching $5.87. The company had a trading volume of 959,053 shares, compared to its average volume of 1,536,686. Amneal Pharmaceuticals has a 1-year low of $1.72 and a 1-year high of $6.46. The stock has a market cap of $1.80 billion, a PE ratio of -18.93 and a beta of 1.33. The firm has a 50 day simple moving average of $5.72 and a 200-day simple moving average of $5.19. The company has a quick ratio of 0.94, a current ratio of 1.63 and a debt-to-equity ratio of 121.31.

Analysts Set New Price Targets

A number of brokerages have issued reports on AMRX. StockNews.com downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, March 4th. Barclays raised their price objective on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an "overweight" rating in a research report on Monday, January 29th. Piper Sandler lifted their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an "overweight" rating in a research report on Thursday, March 21st. Finally, The Goldman Sachs Group lifted their target price on Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a "buy" rating in a research report on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $7.31.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.